David Martin, MD
Cardiovascular Disease · Burlington, MANPI 1215971692
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $20,746 of the $33,144 with a category attached, or 62.6%. Biotronik Inc. accounts for 93.9% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2019 at $19,568 and has fallen 97.8% since, to $437 in 2025.
Across 66 payments — averaging $502.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biotronik Inc.$31K
- Boston Scientific$893
- Medtronic$551
- Abbott$398
- Biosense Webster, Inc.$147
- AstraZeneca$17
- plus $17 from 1 others
What the payments were for
- Speaking & faculty fees$9,00027%
- Travel & lodging$20,74663%
- Food & beverage$3,39810%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biotronik Inc. | 44 | $31,122 |
| Boston Scientific | 8 | $893 |
| Medtronic(2 entities) | 7 | $551 |
| Abbott | 4 | $398 |
| Biosense Webster, Inc. | 1 | $147 |
| AstraZeneca | 1 | $17 |
| Cook Medical LLC | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BioMonitor$2,830
- Edora 8 DR-T$2,781
- Acticor 7 VR-T DX$2,681
- Rivacor 7 DR-T$2,681
- Solia$2,570
- AVEIR$269
- WATCHMAN Access System$177
- GENERAL - THERAPIES$174
- Micra$173
- EMBLEM MRI S-ICD$151
- Rivacor$148
- Acticor$148
- Edora$148
- Zero Gravity$147
- Carto 3$147
How this compares
$33,144 in reported general payments places this provider in the 85th percentile of 750 cardiovascular disease providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 40 | $50,856 |
| XareltoRivaroxaban | 13 | $19,931 |
| Digoxin | 12 | $547 |
| Metoprolol Succinate | 14 | $328 |
| Atorvastatin Calcium | 18 | $276 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Burlington
- Martin MaronBurlington$90K
- Marc SabatineBoston$3.9M
- Elizabeth NabelBoston$2.2M
- Kenneth RosenfieldBoston$1.4M
- Kevin CroceChestnut Hill$1.4M
- James JanuzziBoston$1.1M
- Muthiah VaduganathanBoston$972K
- Joseph LoscalzoBoston$926K
- Sunil KapurBoston$823K
- Paul ZeiBoston$786K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.